RxDoctor Payments Data

Rainer Khetan, MD

Internal Medicine · Dallas, TXNPI 1225059256

Payments from drug & device makers

$7,696in general payments, 2019–2025

Across 415 payments — averaging $18.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$975
  • AbbVie$655
  • GSK$585
  • Novo Nordisk$568
  • Pfizer$553
  • Novartis$486
  • plus $4K from 45 others

What the payments were for

  • Food & beverage$7,696100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,696 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$128,459
Medicare patients
248
Services billed
2,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor13$141,946
MounjaroTirzepatide82$108,000
EliquisApixaban100$106,473
OzempicSemaglutide59$76,548
JardianceEmpagliflozin20$33,461
XareltoRivaroxaban18$29,413
JanuviaSitagliptin Phosphate29$27,556
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$17,764
LinzessLinaclotide20$14,315
Repatha SureclickEvolocumab19$13,508
GemtesaVibegron13$11,221
Breo ElliptaFluticasone/Vilanterol16$7,490
Celecoxib53$4,205
Atorvastatin Calcium328$3,680
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen56$3,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$72$108,00082 claims
PfizerEliquis$553$106,473100 claims
Novo NordiskOzempic$568$76,54859 claims
Boehringer IngelheimJardiance$29$33,46120 claims
Johnson & JohnsonXarelto$93$29,41318 claims
MerckJanuvia$119$27,55629 claims
GSKTrelegy Ellipta, Breo Ellipta$585$25,25435 claims
AbbVieLinzess, Synthroid$655$15,24740 claims
Sumitomo Pharma America, Inc.Gemtesa$153$11,22113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →